2022
DOI: 10.3389/fphar.2022.1062495
|View full text |Cite|
|
Sign up to set email alerts
|

R-carvedilol, a potential new therapy for Alzheimer’s disease

Abstract: For decades, the amyloid cascade hypothesis has been the leading hypothesis in studying Alzheimer’s disease (AD) pathology and drug development. However, a growing body of evidence indicates that simply removing amyloid plaques may not significantly affect AD progression. Alternatively, it has been proposed that AD progression is driven by increased neuronal excitability. Consistent with this alternative hypothesis, recent studies showed that pharmacologically limiting ryanodine receptor 2 (RyR2) open time wit… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 94 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?